Comparing Hyperion DeFi (NASDAQ:HYPD) & SanBio (OTCMKTS:SNBIF)

Hyperion DeFi (NASDAQ:HYPD) and SanBio (OTCMKTS:SNBIF) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, dividends, valuation and analyst recommendations.

Profitability

This table compares Hyperion DeFi and SanBio’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Hyperion DeFi	-62,238.41%	-119.59%	-68.88%
SanBio	N/A	N/A	N/A

Insider & Institutional Ownership

25.8% of Hyperion DeFi shares are owned by institutional investors. 10.9% of Hyperion DeFi shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings and recommmendations for Hyperion DeFi and SanBio, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hyperion DeFi	1	1	1	0	2.00
SanBio	0	1	0	0	2.00

Hyperion DeFi presently has a consensus price target of $3.00, indicating a potential downside of 18.26%. Given Hyperion DeFi’s higher possible upside, equities analysts clearly believe Hyperion DeFi is more favorable than SanBio.

Valuation & Earnings

This table compares Hyperion DeFi and SanBio”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hyperion DeFi	$60,000.00	499.73	-$49.82 million	($4.04)	-0.91
SanBio	N/A	N/A	N/A	N/A	N/A

SanBio has lower revenue, but higher earnings than Hyperion DeFi.

Summary

Hyperion DeFi beats SanBio on 5 of the 8 factors compared between the two stocks.

About Hyperion DeFi

Eyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.

About SanBio

SanBio Company Limited develops, produces, and sells regenerative cell medicines for the central nervous system. The company develops SB623 that has completed a phase 2 clinical trial to treat traumatic brain injury in the United States and Japan. Its research pipeline products also comprise SB623 for ischemic and hemorrhagic strokes, age-related macular degeneration, retinitis pigments, Parkinson’s disease, spinal cord injury, and Alzheimer’s disease; SB618 for peripheral nerve damage; SB308 for muscular dystrophy disease; MSC1 for cancer; and MSC2 for inflammatory disease and optic neuritis. The company was founded in 2001 and is headquartered in Tokyo, Japan.